Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction

Blood

Volumn 93, Issue 9, 1999, Pages 3053-3063

  Wesselborg, Sebastian ^a   Engels, Ingo H ^a   Rossmann, Evi ^a   Los, Marek ^a   Schulze Osthoff, Klaus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; MITOMYCIN C;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

EID: 0033135406     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.9.3053.409a33_3053_3063     Document Type: Article

References (64)

1. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxin and hyperthermia. Biochem Pharmacol 40:2353, 1990
2. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845, 1997
3. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539, 1994
4. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
5. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and a defective myeloid leukemic cells. Cell Growth Differ 4:41, 1993
6. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386, 1996
7. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
8. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329, 1994
9. Zhu H, Fearnhead HO, Cohen GM: An ICE-like protease is a common mediator of apoptosis induced by diverse stimuli in human monocytic THP.1 cells. FEBS Lett 374:303, 1995
10. Chen Z, Naito M, Mashima T, Tsuruo T: Activation of actincleavable interleukin 1β-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Cancer Res 56:5224, 1996
11. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88:1936, 1996
12. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM: Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90:3118, 1997
13. Cohen GM: Caspases: The executioners of apoptosis. Biochem J 326:1, 1997
14. Nicholson DN, Thornberry NA: Caspases: Killer proteases. Trends Biochem Sci 22:299, 1997
15. Cryns V, Yuan J: Proteases to die for. Genes Dev 12:1551, 1998
16. Stroh C, Schulze-Osthoff K: Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ 5:997, 1998
17. Enari M, Sakahiera H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391:43, 1998
18. Kuida K, Zheng TS, Na S, Kuan C, Yang D, Karasuyama H, Rakic P, Flavell RA: Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384:368, 1996
19. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Baumler C, Hellbrandt S, Germer M, Peter ME, Debatin KM: The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 142:175, 1994
20. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME: Apoptosis signaling by death receptors. Eur J Biochem 254:439, 1998
21. Nagata S: Apoptosis by death factor. Cell 88:355, 1997
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85:803, 1996
23. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579, 1995
24. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817, 1996
25. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574, 1996
26. Müller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (Apo-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403, 1997
27. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823, 1997
28. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH: Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90:935, 1997
29. Gamen S, Anel A, Lasierra P, Alava MA, Martinez Lorenzo MJ, Pineiro A, Naval J: Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 417:360, 1997
30. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R: Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 57:3331, 1997
31. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME, Debatin KM: Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57:4956, 1997
32. Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D'Alessandro N, Papoff G, Ruberti G, Rausa L: The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ 5:735, 1998
33. Wajant H, Johannes FJ, Haas E, Siemienski K, Schwenzer R, Schubert G, Weiss T, Grell M, Scheurich P: Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr Biol 8:113, 1998
34. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271, 1991
35. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976, 1993
36. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801, 1995
37. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME: FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 16:2794, 1997
38. Scaffidi C, Medema JP, Krammer PH, Peter ME: FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem 272:26953, 1997
39. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, Xing L, Gentz R, Ni J, Dixit VM: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274:990, 1996
40. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science 276:111, 1997
41. Walczak H, Degli Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT: TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386, 1997
42. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-KB pathway. Immunity 7:821, 1997
43. Schneider P, Thome M, Burs K, Bodmer JL, Hofman K, Kataoka T, Holler N, Tschopp J: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-KB. Immunity 7:831, 1997
44. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815, 1997
45. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM: Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16:6200, 1998
46. Strasser A, Harris AW, Huang DC, Krammer PH, Cory S: Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14:6136, 1995
47. Smith KG, Strasser A, Vaux DL: CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease. EMBO J 15:5167, 1996
48. Kluck RM, Bossy Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275:1132, 1997
49. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129, 1997
50. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A: A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 17:706, 1998
51. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin K-M, Krammer P, Peter ME: Two CD95 (Apo-1/Fas) signaling pathways. EMBO J 17:1675, 1998
52. Adachi S, Cross AR, Babior BM, Gottlieb RA: Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. J Biol Chem 272:21878, 1997
53. L as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94:6939, 1997
54. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein, homologous to C. elegans Ced-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405, 1997
55. Hofmann K, Bucher P, Tschopp J: The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci 22:155, 1997
56. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM: Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death. Science 275:1122, 1997
57. Moreno MB, Memon SA, Zacharchuk CM: Apoptosis signaling pathways in normal T cells: Differential activity of Bcl-2 and IL-1β-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. J Immunol 157:3845, 1996
58. L. J Biol Chem 271:17601, 1996
59. Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW: FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954, 1998
60. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 377:630, 1995
61. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189, 1995
62. Seino K, Kayagaki N, Okumura K, Yagita H: Antitumor effect of locally produced CD95 ligand. Nat Med 3:165, 1997
63. Allison J, Georgiou HM, Strasser A, Vaux DL: Transgenic expression of CD95 ligand on islet β-cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 94:3943, 1997
64. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock OG, Baekkeskov S: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3:738, 1997